mercredi 20 avril 2016

Onco Actu du 20 avril 2016

3.1 Tabac

FDA launches first ad campaign focused on dangers of smokeless tobacco among rural teens [FDA]

U.S. House committee votes to smooth e-cigarette regulatory path [Reuters]

5. Traitements

What A Toddler And Her Tumor Can Teach Us About Cancer Research [Forbes]

5.12 Immunothérapies

The list of cancers that can be treated by immunotherapy keeps growing [Washington Post]

Immuno-oncology market to hit $34 billion by 2024 [European Pharmaceutical Review]

5.2 Pharma

Pfizer Announces Positive Top-Line Results for Phase 3 PALOMA-2 Clinical Trial of IBRANCE® (palbociclib) [Pfizer]

5.2.2 Pharma - Fusions & Acquisitions

OSE Pharma, effimune mergiong to create European immunotherapy company [Pharma Intelligence]

5.9.1 AACR - sein

Agendia’s MammaPrint® First and Only Genomic Assay to Receive Level 1A Clinical Utility Evidence for Chemotherapy Benefit in Early Breast Cancer Patients [Agendia]

Test could spare breast cancer patients unnecessary chemotherapy [Cancer Research UK]

5.9.4 AACR - poumon

ARIAD Announces Results of Preclinical Studies on AP32788 at the Annual Meeting of the American Association for Cancer Research [ARIAD]

5.9.5 AACR - T-cell immunothérapies

Kite Pharma Presents Updated Phase 1 Results from ZUMA-1 at the American Association of Cancer Research (AACR) Annual Meeting [Kite]

New Technology Can Potentially Overcome CAR T-cell Immunotherapy Limitations [AACR]

5.9.7 AACR - divers

AACR 2016: CRISPR as a Screening Tool for Drug Targets [GEN]

An Implantable Microdevice Has Potential to Identify Suitable Therapy for Cancer Patients [AACR]

New Mathematical Model May Help Better Define Roles of Environmental and Intrinsic Factors in Cancer Initiation [AACR]

Noninvasive Test Detected Colorectal Cancer in Previously Unscreened Patients [AACR]

​Certain Oral Bacteria Associated With Increased Pancreatic Cancer Risk​ [AACR]

5.9.9 AACR - immunothérapies

​​​Pembrolizumab Yielded Durable Responses in Patients With Advanced Merkel Cell Carcinoma [AACR]

First Presentation of Overall Survival Data for Opdivo® (nivolumab) Shows Significant Survival Benefit at One-Year Versus Investigator’s Choice in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck [BMS]

Nivolumab Improved Survival For Patients With Head and Neck Squamous Cell Carcinoma [AACR]

Studies show continued promise for immunotherapy drugs [Cancer Research UK]

Drug doubles chance of surviving head and neck cancer for a year, trial shows [The Telegraph]

AACR Annual Meeting 2016: Exciting Immunotherapy Advances Confirm Long-term Benefit, Offer Hope for More Cancer Types [CANCER RESEARCH Catalyst]

Bristol-Myers' Opdivo extends survival in head and neck cancer -study [Reuters]

6. Lutte contre les cancers

Uganda's only cancer treatment machine breaks, patients left waiting [Reuters]

6.10 Politiques

Windfall for cancer research sets off a scramble for clout [STAT]

6.4 Médico-éco

Personalised medicine in the US: does higher spending mean better care? [PHG Foundation]

6.5 Médecines alternatives

Another young woman with cancer, lured into quackery by Ty Bollinger [Respectful Insolence]

6.7 DMP, Big Data & applis

European Cloud Initiative to boost Europe's data-driven economy [PHG Foundation]

6.9 Controverses

NIH Halts Some Research Amid Concerns Over Contamination And Safety [NPR]

Statement on Review of NIH Sterile Production Facilities [National Institutes of Health]